2. Search Result
Search Result
Results for "

vasopressin V2 receptor

" in MedChemExpress (MCE) Product Catalog:

42

Inhibitors & Agonists

8

Peptides

1

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-18347A
    Conivaptan hydrochloride
    10+ Cited Publications

    YM 087

    		 Vasopressin Receptor Cardiovascular Disease Endocrinology
    Conivaptan (hydrochloride) is a non-peptide antagonist of vasopressin receptor, with Ki values of 0.48 and 3.04 nM for rat liver V1A receptor and rat kidney V2 receptor respectively.
    Conivaptan hydrochloride
  • HY-P0049
    Argipressin
    5+ Cited Publications

    Arg8-vasopressin; AVP

    		 Vasopressin Receptor Neurological Disease Cancer
    Argipressin (Arg8-vasopressin) binds to the V1, V2, V3-vascular arginine vasopressin receptor, with a Kd value of 1.31 nM in A7r5 rat aortic smooth muscle cells for V1.
    Argipressin
  • HY-17000
    Tolvaptan
    Maximum Cited Publications
    19 Publications Verification

    OPC-41061

    		 Vasopressin Receptor Autophagy Cardiovascular Disease Endocrinology Cancer
    Tolvaptan is a selective, competitive and orally active vasopressin receptor 2 (V2R) antagonist with an IC50 of 1.28 μM for the inhibition of arginine vasopressin (AVP)-induced platelet aggregation. Tolvaptan induces cell apoposis and affects cell cycle. Tolvaptan can be used for the research of hyponatremia .
    Tolvaptan
  • HY-119706
    Barbadin
    15+ Cited Publications

    		 Apoptosis Arrestin Others
    Barbadin is a novel and selective β-arrestin/β2-adaptin interaction inhibitor, has IC50 values of 19.1 μM for β-arrestin1 and 15.6 μM for β-arrestin2. Barbadin blocks agonist-promoted endocytosis of the prototypical β2-adrenergic, V2-vasopressin and angiotensin-II type-1 receptors. Barbadin can induce apoptosis .
    Barbadin
  • HY-14185
    Lixivaptan
    4 Publications Verification

    VPA-985; WAY-VPA 985

    		 Vasopressin Receptor Cardiovascular Disease Endocrinology
    Lixivaptan (VPA-985, WAY-VPA 985) is an orally active and selective vasopressin receptor V2 antagonist, with IC50 values of 1.2 and 2.3 nM for human and rat V2, respectively.
    Lixivaptan
  • HY-124733A
    LIT-001

    		Oxytocin Receptor Neurological Disease
    LIT-001 is the first nonpeptide oxytocin receptor (OT-R) agonist (EC50=55 nM; Ki=226 nM). LIT-001 improves social interaction in a mouse model of autism .
    LIT-001
  • HY-18346
    Mozavaptan
    1 Publications Verification

    OPC-31260

    		 Vasopressin Receptor Cardiovascular Disease Metabolic Disease Endocrinology Cancer
    Mozavaptan (OPC-31260) is a benzazepine derivative and a potent, selective, competitive and orally active vasopressin V2 receptor antagonist with an IC50 of 14 nM. Mozavaptan shows ~85-fold selectivity for V2 receptor over V1 receptor (IC50 of 1.2 μM), and can antagonize the antidiuretic action of arginine vasopressin (AVP) in vivo. Mozavaptan has the potential for hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), and congestive heart failure treatment .
    Mozavaptan
  • HY-W539944
    Argipressin acetate
    5+ Cited Publications

    Arg8-vasopressin acetate; AVP acetate

    		 Vasopressin Receptor Apoptosis Neurological Disease Cancer
    Argipressin (Arg8-vasopressin) (acetate) binds to the V1, V2, V3-vascular arginine vasopressin receptor, with a Kd value of 1.31 nM in A7r5 rat aortic smooth muscle cells for V1 .
    Argipressin acetate
  • HY-19381
    WAY-151932

    VNA-932; WAY-VNA 932

    		 Vasopressin Receptor Metabolic Disease Endocrinology
    WAY-151932 is a vasopressin V2-receptor agonist with IC50 of 80.3 nM and 778 nM in human-V2 binding and V1a binding assay.
    WAY-151932
  • HY-146272
    Vasopressin V2 receptor antagonist 1

    		Vasopressin Receptor Endocrinology
    Vasopressin V2 receptor antagonist 1 is a vasopressin V2 receptor (V2R) antagonist with a Ki value of 3.8 nM. Vasopressin V2 receptor antagonist 1 inhibits renal cyst formation in embryonic renal cyst models and mouse models. Vasopressin V2 receptor antagonist 1 can be used in research related to autosomal dominant polycystic kidney disease .
    Vasopressin V2 receptor antagonist 1
  • HY-14887
    Fedovapagon
    1 Publications Verification

    VA106483

    		 Vasopressin Receptor Metabolic Disease
    Fedovapagon (VA106483) is a selective and orally active vasopressin V2 receptor (V2R) agonist with an EC50 of 24 nM. Fedovapagon can be used in the research of nocturia .
    Fedovapagon
  • HY-123593
    Mozavaptan hydrochloride
    1 Publications Verification

    OPC-31260 hydrochloride

    		 Vasopressin Receptor Cardiovascular Disease Metabolic Disease Endocrinology Cancer
    Mozavaptan hydrochloride (OPC-31260 hydrochloride) is a benzazepine derivative and a potent, selective, competitive and orally active vasopressin V2 receptor antagonist with an IC50 of 14 nM. Mozavaptan hydrochloride shows ~85-fold selectivity for V2 receptor over V1 receptor (IC50 of 1.2 μM), and can antagonize the antidiuretic action of arginine vasopressin (AVP) in vivo. Mozavaptan hydrochloride has the potential for hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), and congestive heart failure treatment .
    Mozavaptan hydrochloride
  • HY-105685
    SRX246

    		Vasopressin Receptor Cardiovascular Disease Neurological Disease
    SRX246 is a potent, BBB-penetrant, highly selective vasopressin 1a (V1a) receptor antagonist (Ki=0.3 nM for human V1a). SRX246 has no interaction at V1b and V2 receptors. SRX246 also displays negligible binding at 64 others receptors classes, including 35 G-proteincoupled receptors. SRX246 can be used for treatment of stress-related disorders .
    SRX246
  • HY-162394
    Vasopressin V2 receptor antagonist 2

    		Vasopressin Receptor Metabolic Disease
    Vasopressin V2 receptor antagonist 2 (Compound 33) is an antagonist of the arginine vasopressin V2 receptor (V2R) with a Ki value of 6.2 nM. Vasopressin V2 receptor antagonist 2 can effectively reduce cAMP levels, thereby inhibiting the growth of renal cysts[1].
    Vasopressin V2 receptor antagonist 2
  • HY-116567
    OPC-51803

    		Vasopressin Receptor Metabolic Disease
    OPC-51803 is an orally active nonpeptide vasopressin V2 receptor agonist. OPC-51803 can be used for the research of micturition disorders that result in frequent micturition, such as that from polyuria, nocturnal polyuria, and some kinds of urinary incontinence .
    OPC-51803
  • HY-P1390
    d[Cha4]-AVP

    		Vasopressin Receptor Endocrinology
    d[Cha4]-AVP is a potent and selective vasopressin (AVP) V1b receptor agonist with a Ki of 1.2 nM for human V1b receptor. d[Cha4]-AVP shows more selective for V1b receptor than human V1a receptor, V2 receptor, and oxytocin receptors .
    d[Cha4]-AVP
  • HY-18347
    Conivaptan

    YM 087 free base

    		 Vasopressin Receptor Cardiovascular Disease
    Conivaptan (YM 087 free base) is antagonist for vasopressin V1A receptor and vasopressin V2 receptor. Conivaptan ameliorates congestive heart failure, improves cardiac systolic function .
    Conivaptan
  • HY-18344
    Satavaptan

    SR 121463

    		 Vasopressin Receptor Metabolic Disease
    Satavaptan (SR 121463) is an antagonist for vasopressin V2 receptor. Satavaptan regulates the vasopressin regulated phosphopeptides and vasopressin-mediated signaling pathway. Satavaptan is potential in ameliorating hyponatremia .
    Satavaptan
  • HY-116567A
    (S)-OPC-51803

    		Endogenous Metabolite Endocrinology
    (S)-OPC-51803 is an agonist of the vasopressin V2 receptor, with activity in suppressing nocturia and urinary incontinence. (S)-OPC-51803 was evaluated in terms of biological activity and showed a stronger V2 receptor agonist effect compared to its (R)-isomer. The use of (S)-OPC-51803 may improve the patient's ability to control nocturnal polyuria .
    (S)-OPC-51803
  • HY-18346R
    Mozavaptan (Standard)

    OPC-31260 (Standard)

    		 Vasopressin Receptor Reference Standards Cardiovascular Disease Metabolic Disease Endocrinology Cancer
    Mozavaptan (Standard) is the analytical standard of Mozavaptan. This product is intended for research and analytical applications. Mozavaptan (OPC-31260) is a benzazepine derivative and a potent, selective, competitive and orally active vasopressin V2 receptor antagonist with an IC50 of 14 nM. Mozavaptan shows ~85-fold selectivity for V2 receptor over V1 receptor (IC50 of 1.2 μM), and can antagonize the antidiuretic action of arginine vasopressin (AVP) in vivo. Mozavaptan has the potential for hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), and congestive heart failure treatment .
    Mozavaptan (Standard)
  • HY-157220
    Tolvaptan phosphate ester sodium

    		Vasopressin Receptor Cardiovascular Disease
    Tolvaptan phosphate ester sodium, a prodrug of Tolvaptan (HY-17000), can be used in the study of cardiac edema. Tolvaptan is a selective, competitive and orally active vasopressin receptor 2 (V2R) antagonist with an IC50 of 1.28 μM for the inhibition of arginine vasopressin (AVP)-induced platelet aggregation .
    Tolvaptan phosphate ester sodium
  • HY-P1390A
    d[Cha4]-AVP TFA

    		Vasopressin Receptor Endocrinology
    d[Cha4]-AVP TFA is a potent and selective vasopressin (AVP) V1b receptor agonist with a Ki of 1.2 nM for human V1b receptor. d[Cha4]-AVP TFA shows more selective for V1b receptor than human V1a receptor, V2 receptor, and oxytocin receptors .
    d[Cha4]-AVP TFA
  • HY-109181
    Lazuvapagon

    SK-1404; KRP-N118

    		 Vasopressin Receptor Others
    Lazuvapagon (SK-1404) is a vasopressin V2 receptor agonist for the research of nocturia .
    Lazuvapagon
  • HY-14185R
    Lixivaptan (Standard)

    VPA-985 (Standard); WAY-VPA 985 (Standard)

    		 Vasopressin Receptor Reference Standards Cardiovascular Disease Endocrinology
    Lixivaptan (Standard) is the analytical standard of Lixivaptan. This product is intended for research and analytical applications. Lixivaptan (VPA-985, WAY-VPA 985) is an orally active and selective vasopressin receptor V2 antagonist, with IC50 values of 1.2 and 2.3 nM for human and rat V2, respectively.
    Lixivaptan (Standard)
  • HY-123593R
    Mozavaptan hydrochloride (Standard)

    OPC-31260 hydrochloride (Standard)

    		 Vasopressin Receptor Reference Standards Cardiovascular Disease Metabolic Disease Endocrinology Cancer
    Mozavaptan (hydrochloride) (Standard) is the analytical standard of Mozavaptan (hydrochloride). This product is intended for research and analytical applications. Mozavaptan hydrochloride (OPC-31260 hydrochloride) is a benzazepine derivative and a potent, selective, competitive and orally active vasopressin V2 receptor antagonist with an IC50 of 14 nM. Mozavaptan hydrochloride shows ~85-fold selectivity for V2 receptor over V1 receptor (IC50 of 1.2 μM), and can antagonize the antidiuretic action of arginine vasopressin (AVP) in vivo. Mozavaptan hydrochloride has the potential for hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), and congestive heart failure treatment .
    Mozavaptan hydrochloride (Standard)
  • HY-18346S
    Mozavaptan-d6

    OPC-31260-d6

    		 Isotope-Labeled Compounds Vasopressin Receptor Metabolic Disease Endocrinology Cancer
    Mozavaptan-d6 (OPC-31260-d6) is the deuterium labeled Mozavaptan. Mozavaptan (OPC-31260) is a benzazepine derivative and a potent, selective, competitive and orally active vasopressin V2 receptor antagonist with an IC50 of 14 nM. Mozavaptan shows ~85-fold selectivity for V2 receptor over V1 receptor (IC50 of 1.2 μM), and can antagonize the antidiuretic action of arginine vasopressin (AVP) in vivo. Mozavaptan has the potential for hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), and congestive heart failure treatment .
    Mozavaptan-d6
  • HY-18347AR
    Conivaptan hydrochloride (Standard)

    YM 087 (Standard)

    		 Reference Standards Vasopressin Receptor Cardiovascular Disease Endocrinology
    Conivaptan (hydrochloride) (Standard) is the analytical standard of Conivaptan (hydrochloride). This product is intended for research and analytical applications. Conivaptan (hydrochloride) is a non-peptide antagonist of vasopressin receptor, with Ki values of 0.48 and 3.04 nM for rat liver V1A receptor and rat kidney V2 receptor respectively.
    Conivaptan hydrochloride (Standard)
  • HY-P5213
    Vasopressin Dimer (parallel) TFA

    		Vasopressin Receptor Oxytocin Receptor Endocrinology
    Vasopressin Dimer (parallel) TFA is a parallel dimer of Vasopressin (HY-B1811). Vasopressin Dimer (parallel) TFA can activate four G protein-coupled receptors, V1aR, V1bR, V2R, and OTR .
    Vasopressin Dimer (parallel) TFA
  • HY-120285
    M-0002 hydrochloride

    RWJ-351647 hydrochloride; SPD-556 hydrochloride

    		 Endogenous Metabolite Endocrinology
    M-0002 hydrochloride (RWJ-351647 hydrochloride) is a biologically active compound that acts as an antagonist of the vasopressin V2 receptor. M-0002 hydrochloride is potentially useful for inhibiting ascites. M-0002 hydrochloride shows excellent properties that are favorable for clinical development .
    M-0002 hydrochloride
  • HY-17000R
    Tolvaptan (Standard)

    OPC-41061 (Standard)

    		 Reference Standards Vasopressin Receptor Autophagy Cardiovascular Disease Endocrinology Cancer
    Tolvaptan (Standard) is the analytical standard of Tolvaptan. This product is intended for research and analytical applications. Tolvaptan is a selective, competitive and orally active vasopressin receptor 2 (V2R) antagonist with an IC50 of 1.28 μM for the inhibition of arginine vasopressin (AVP)-induced platelet aggregation. Tolvaptan induces cell apoposis and affects cell cycle. Tolvaptan can be used for the research of hyponatremia .
    Tolvaptan (Standard)
  • HY-165423
    DM-4111

    		Vasopressin Receptor Drug Metabolite Cardiovascular Disease
    DM-4111, one of the major monohydroxyl metabolites of Tolvaptan (HY-17000), is a potent vasopressin V2 receptor inhibitor. DM-4111 inhibits water reabsorption in the renal tubules, thereby promoting the excretion of electrolyte-free water. DM-4111 is promising for research of cardiovascular diseases .
    DM-4111
  • HY-124733
    LIT-001 free base

    		Oxytocin Receptor Neurological Disease
    LIT-001 free base is the first nonpeptide oxytocin receptor (OT-R) agonist (EC50=55 nM; Ki=226 nM). LIT-001 free base improves social interaction in a mouse model of autism .
    LIT-001 free base
  • HY-P5010
    (D-Arg8)-Inotocin

    		Vasopressin Receptor Cardiovascular Disease
    (D-Arg8)-Inotocin is a potent, selective and competitive antagonist of vasopressin receptor (V1aR), with a Ki of 1.3 nM. (D-Arg8)-Inotocin shows more than 3000-fold selectivity for the human V1aR over the other three subtypes, OTR, V1bR and V2R .
    (D-Arg8)-Inotocin
  • HY-118918
    YM218 free base

    		Vasopressin Receptor Endocrinology
    YM218 free base is an orally active non-peptide vasopressin (AVP) receptor antagonist. YM218 free base has a high affinity for rat liver V1A receptors with a Ki value of 0.50 nM; it has a lower affinity for rat pituitary V1B, kidney V2, and uterine oxytocin receptors with Ki values of 1510 nM, 72.2 nM, and 150 nM, respectively. YM218 free base can be used in the study of diabetes and kidney disease .
    YM218 free base
  • HY-116066
    YM471 free base

    		Endogenous Metabolite Endocrinology
    YM471 free base is a non-peptide antagonist of vasopressin V1A and V2 receptors with potent and persistent antagonistic activity. YM471 exhibits high affinity for rat V1A and V2 receptors with K values of 0.16 and 0.77 nM, respectively .
    YM471 free base
  • HY-186040
    ASP-7035

    		Vasopressin Receptor Neurological Disease
    ASP-7035 (compound 55) is an arginine vasopressin V2 receptor agonist. ASP-7035 can be used in the research of nocturia .
    ASP-7035
  • HY-P5214
    Vasopressin Dimer (anti-parallel) TFA

    		Vasopressin Receptor Oxytocin Receptor Endocrinology
    Vasopressin Dimer (anti-parallel) TFA is an anti-parallel dimer of Vasopressin (HY-B1811). Vasopressin Dimer (anti-parallel) TFA can activate four G protein-coupled receptors, V1aR, V1bR, V2R, and OTR .
    Vasopressin Dimer (anti-parallel) TFA
  • HY-19880
    RWJ-676070

    		Vasopressin Receptor Endocrinology
    RWJ-676070 is a dual vasopressin V(1A)/V(2) receptor antagonist with an Ki value of 1.4 nM and 14 nM respectly .
    RWJ-676070
  • HY-17000A
    (R)-(+)-Tolvaptan

    (R)-(+)-OPC-41061

    		 Vasopressin Receptor Others
    (R)-(+)-Tolvaptan ((R)-(+)-OPC-41061) is the (R)-(+) enantiomer of Tolvaptan (HY-17000). Tolvaptan (OPC-41061) is a selective, competitive and orally active vasopressin receptor 2 (V2R) antagonist .
    (R)-(+)-Tolvaptan
  • HY-180142
    XYDC2050

    		Vasopressin Receptor Endocrinology
    XYDC2050 (Compound 29) is a selective vasopressin V2 receptor (V2R) antagonist with an IC50 of 27 nM and a Ki of 2.8 nM. XYDC2050 shows a Ki of 420.7 nM (SI = 162 fold) for V1R. XYDC2050 can inhibit Vasopressin (HY-B1811)-induced intracellular cyclic adenosine monophosphate (cAMP) accumulation with an IC50 of 12 nM. XYDC2050 can inhibit the growth of renal cysts, reduce the ratio of kidney weight to body weight and decrease the area of cysts and the cystic index. XYDC2050 can be used for the research of autosomal dominant polycystic kidney disease (ADPKD) .
    XYDC2050
  • HY-105685R
    SRX246 (Standard)

    		Reference Standards Vasopressin Receptor Cardiovascular Disease Neurological Disease
    SRX246 (Standard) is the analytical standard of SRX246 (HY-105685). This product is intended for research and analytical applications. SRX246 is a potent, BBB-penetrant, highly selective vasopressin 1a (V1a) receptor antagonist (Ki=0.3 nM for human V1a). SRX246 has no interaction at V1b and V2 receptors. SRX246 also displays negligible binding at 64 others receptors classes, including 35 G-proteincoupled receptors. SRX246 can be used for treatment of stress-related disorders .
    SRX246 (Standard)
  • HY-165456
    AGN-190851

    		Adrenergic Receptor Vasopressin Receptor Endocrinology
    AGN-190851 is a potent and selective agonist of α2-adrenergic receptor (α2 adrenoceptor). AGN-190851 induces dose-dependent water diuresis in rats, and inhibits vasopressin V2 receptor in a species-dependent manner in vitro, thereby suppressing cAMP production. AGN-190851 enhances the contraction of porcine myometrium. AGN 190851 can be used in studies on renal diuretic mechanisms, pharmacology of α2-adrenergic receptor subtypes, and parturition .
    AGN-190851

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: